JDQ443,tislelizumab
Novartis,Beigene
['jdq443']
jdq443 is a kras g12c inhibitor with reasonable and expected efficacy and toxicity data. ability to combine safely with apd1 without hepatitis will be key differentiator amongst agents in this class #mediq23asco, #asco23 
Professor, Medical Oncology @UCSD; PI @Patel_Lab computational immunopathology; Phase 1 & thoracic/NSCLC immunotherapy, solid tumor cell therapy, irAEs (he/him)